MC
VIVO

Maverick Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Maverick Capital’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,039
Closed -$393K – 906
2020
Q4 		$393K Buy
+21,039
New +$393K 0.01% 404

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Maverick Capital's VIVO Position: Q1 2021 in Review

Maverick Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2021, closing a stake of 21,039 shares — an estimated $393K sold.

Maverick Capital first reported a position in VIVO in Q4 2020 and held it in 1 quarter. The position peaked at $393K in Q4 2020. 215 funds tracked by Wall St. Rank hold VIVO as of Q1 2021.

  • Maverick Capital reported no remaining Meridian Bioscience Inc position as of Q1 2021 after selling out during the quarter.
  • Maverick Capital sold 21,039 Meridian Bioscience Inc shares in Q1 2021, an estimated $393K.
  • Maverick Capital first reported a position in Meridian Bioscience Inc in Q4 2020 and held it in 1 quarter.
  • Maverick Capital's Meridian Bioscience Inc position peaked at $393K in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.